
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Managing A Case of Heavily Pretreated Recurrent Ovarian Cancer
Case: A 58-Year-Old Female With Heavily Pretreated Recurrent Ovarian Cancer
H & P






